LifePoint to start clinical trials for Impact system:
This article was originally published in Clinica
Executive Summary
LifePoint is set to begin a US and Canadian multicentre clinical trials of its rapid, saliva-based drugs-of-abuse/alcohol Impact test system. The test, which the company claims is the only product of its kind that can perform alcohol and drug testing simultaneously, detectS markers in saliva and correlates them to equivalent levels in blood. Data generated from the trial will form the basis of the Ontario, California company's 510(k) marketing application to the FDA.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.